This was consistent with the previous report that patients with a HER2-negative breast cancer benefitted from paclitaxel, regardless of estrogen-receptor status, but paclitaxel treatment did not benefit patients with HER2-negative cancers (like that of HCC1937) [16]. This evidence concerns the gene ESR1 and cancer.